Valuation : IXICO plc

Market Cap 1.64Cr 2.21Cr 1.91Cr 1.8Cr 3.07Cr 211.26Cr 3.08Cr 21Cr 8.24Cr 107.43Cr 8.3Cr 8.12Cr 339.31Cr P/E 2026 *
-5.36x
P/E 2027 * -5.77x
Enterprise Value 61.54L 83.21L 71.74L 67.89L 1.15Cr 79Cr 1.16Cr 8.07Cr 3.1Cr 40Cr 3.12Cr 3.06Cr 127.68Cr EV / Sales 2026 *
0.77x
EV / Sales 2027 * 1.14x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 2.21Cr
-0.71%-6.35%-2.99%+9.59% 4.55TCr
+0.21%-2.98%+337.74%+519.55% 4.37TCr
+1.74%-2.24%+39.82%+20.76% 4.31TCr
+1.38%-3.28%+6.84%+67.62% 3.94TCr
-1.44%-5.26%+8.97%+39.76% 3.19TCr
+0.87%-2.60% - - 1.73TCr
+0.75%-0.64%+19.75%+110.17% 1.64TCr
-0.31%-2.78%+10.78%+31.02% 1.42TCr
+1.93%-3.55%+82.00%+41.17% 1.33TCr
Average -4.89%-3.57%+62.86%+104.96% 2.94TCr
Weighted average by Cap. +0.41%-3.67%+74.57%+124.26%

Financials

2026 *2027 *
Net sales 80L 1.08Cr 93.26L 88.26L 1.5Cr 103.35Cr 1.51Cr 10Cr 4.03Cr 53Cr 4.06Cr 3.97Cr 165.99Cr 90L 1.22Cr 1.05Cr 99.29L 1.69Cr 116.27Cr 1.7Cr 12Cr 4.54Cr 59Cr 4.57Cr 4.47Cr 186.74Cr
Net income -21.43L -28.98L -24.98L -23.64L -40.18L -28Cr -40.42L -2.81Cr -1.08Cr -14Cr -1.09Cr -1.06Cr -44Cr -28.01L -37.87L -32.65L -30.9L -52.52L -36Cr -52.83L -3.67Cr -1.41Cr -18Cr -1.42Cr -1.39Cr -58Cr
Net Debt -1.02Cr -1.38Cr -1.19Cr -1.13Cr -1.91Cr -131.77Cr -1.92Cr -13Cr -5.14Cr -67Cr -5.18Cr -5.06Cr -211.64Cr -61L -82.48L -71.11L -67.3L -1.14Cr -79Cr -1.15Cr -8Cr -3.07Cr -40Cr -3.1Cr -3.03Cr -126.57Cr
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0750GBP
Average target price
0.2600GBP
Spread / Average Target
+246.67%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!